Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7161875rdf:typepubmed:Citationlld:pubmed
pubmed-article:7161875lifeskim:mentionsumls-concept:C0006684lld:lifeskim
pubmed-article:7161875lifeskim:mentionsumls-concept:C0002962lld:lifeskim
pubmed-article:7161875lifeskim:mentionsumls-concept:C0002963lld:lifeskim
pubmed-article:7161875lifeskim:mentionsumls-concept:C0002965lld:lifeskim
pubmed-article:7161875lifeskim:mentionsumls-concept:C0028066lld:lifeskim
pubmed-article:7161875lifeskim:mentionsumls-concept:C0035253lld:lifeskim
pubmed-article:7161875lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:7161875pubmed:issue6lld:pubmed
pubmed-article:7161875pubmed:dateCreated1983-4-21lld:pubmed
pubmed-article:7161875pubmed:abstractTextThe effects of drugs were evaluated in 47 cases with variant angina (VA), 19 with resting angina showing ST depression (RA), and 84 with unstable angina (UA). In VA patients, calcium antagonists were effective in 87.1% of the cases, while other drugs were effective in 56.3%. The difference was statistically significant. In RA patients, calcium antagonists were effective in 80.0% of the cases and other drugs in 44.4%. Nifedipine was effective in all 5 cases with coronary stenosis of more than 75.0%. All cases of RA had multiple vessel disease and nifedipine was effective in 80.0% of the patients. Nifedipine was effective in 83.3% of VA cases showing ST elevation during an exercise test, and was particularly effective in all patients having attacks only at rest. The effects of nifedipine were confirmed in 83.3% of UA cases. These results indicate that calcium antagonists are effective in VA, RA, and UA.lld:pubmed
pubmed-article:7161875pubmed:languageenglld:pubmed
pubmed-article:7161875pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7161875pubmed:citationSubsetIMlld:pubmed
pubmed-article:7161875pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7161875pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7161875pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7161875pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7161875pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7161875pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7161875pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7161875pubmed:statusMEDLINElld:pubmed
pubmed-article:7161875pubmed:monthNovlld:pubmed
pubmed-article:7161875pubmed:issn0021-4868lld:pubmed
pubmed-article:7161875pubmed:authorpubmed-author:KimuraEElld:pubmed
pubmed-article:7161875pubmed:authorpubmed-author:HayakawaHHlld:pubmed
pubmed-article:7161875pubmed:authorpubmed-author:TakayamaMMlld:pubmed
pubmed-article:7161875pubmed:authorpubmed-author:OtteWWlld:pubmed
pubmed-article:7161875pubmed:authorpubmed-author:KishidaHHlld:pubmed
pubmed-article:7161875pubmed:authorpubmed-author:KusamaYYlld:pubmed
pubmed-article:7161875pubmed:issnTypePrintlld:pubmed
pubmed-article:7161875pubmed:volume23lld:pubmed
pubmed-article:7161875pubmed:ownerNLMlld:pubmed
pubmed-article:7161875pubmed:authorsCompleteYlld:pubmed
pubmed-article:7161875pubmed:pagination871-81lld:pubmed
pubmed-article:7161875pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:7161875pubmed:meshHeadingpubmed-meshheading:7161875-...lld:pubmed
pubmed-article:7161875pubmed:meshHeadingpubmed-meshheading:7161875-...lld:pubmed
pubmed-article:7161875pubmed:meshHeadingpubmed-meshheading:7161875-...lld:pubmed
pubmed-article:7161875pubmed:meshHeadingpubmed-meshheading:7161875-...lld:pubmed
pubmed-article:7161875pubmed:meshHeadingpubmed-meshheading:7161875-...lld:pubmed
pubmed-article:7161875pubmed:meshHeadingpubmed-meshheading:7161875-...lld:pubmed
pubmed-article:7161875pubmed:meshHeadingpubmed-meshheading:7161875-...lld:pubmed
pubmed-article:7161875pubmed:meshHeadingpubmed-meshheading:7161875-...lld:pubmed
pubmed-article:7161875pubmed:meshHeadingpubmed-meshheading:7161875-...lld:pubmed
pubmed-article:7161875pubmed:meshHeadingpubmed-meshheading:7161875-...lld:pubmed
pubmed-article:7161875pubmed:meshHeadingpubmed-meshheading:7161875-...lld:pubmed
pubmed-article:7161875pubmed:meshHeadingpubmed-meshheading:7161875-...lld:pubmed
pubmed-article:7161875pubmed:meshHeadingpubmed-meshheading:7161875-...lld:pubmed
pubmed-article:7161875pubmed:meshHeadingpubmed-meshheading:7161875-...lld:pubmed
pubmed-article:7161875pubmed:meshHeadingpubmed-meshheading:7161875-...lld:pubmed
pubmed-article:7161875pubmed:meshHeadingpubmed-meshheading:7161875-...lld:pubmed
pubmed-article:7161875pubmed:year1982lld:pubmed
pubmed-article:7161875pubmed:articleTitleEffects of calcium antagonists, especially nifedipine, on variant angina, resting angina, and unstable angina.lld:pubmed
pubmed-article:7161875pubmed:publicationTypeJournal Articlelld:pubmed